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http://dx.doi.org/10.1016/j.ccr.2013.03.021SUMMARYPIK3CA, which encodes the p110a catalytic subunit of phosphatidylinositol 3-kinase a, is frequently mutated
in human cancers. Most of these mutations occur at two hot-spots: E545K and H1047R located in the helical
domain and the kinase domain, respectively. Here, we report that p110a E545K, but not p110aH1047R, gains
the ability to associate with IRS1 independent of the p85 regulatory subunit, thereby rewiring this oncogenic
signaling pathway. Disruption of the IRS1-p110a E545K interaction destabilizes the p110a protein, reduces
AKT phosphorylation, and slows xenograft tumor growth of a cancer cell line expressing p110a E545K.More-
over, a hydrocarbon-stapled peptide that disrupts this interaction inhibits the growth of tumors expressing
p110a E545K.INTRODUCTION
PIK3CA is frequently mutated in a variety of human cancers
including colorectal cancers (CRCs) (Bachman et al., 2004; Bro-
derick et al., 2004; Campbell et al., 2004; Lee et al., 2005; Levine
et al., 2005; Li et al., 2005; Oda et al., 2005; Samuels et al., 2004).
PIK3CA encodes the catalytic subunit of phosphatidylinositol
3-kinase a (PI3Ka), which plays a key role in regulating cell pro-
liferation, survival, and motility (Liu et al., 2009; Zhao and Vogt,
2008a). PI3Ka consists of a catalytic subunit p110a and one
of several regulatory subunits (a major one being p85a). The
p110a subunit contains an N-terminal adaptor-binding domainSignificance
PIK3CA is the most frequently mutated oncogene in a variety
mutant enzyme for cancer therapy. However, it remains a challe
show that disruption of the interactions between helical domain
sible target for cancer therapy, thereby providing proof-of-pri
mutations.(ABD), a Ras-binding domain (RBD), a C2 domain, a helical
domain, and a catalytic domain (Amzel et al., 2008). In the basal
state, the regulatory p85 subunit stabilizes the catalytic p110a
subunit and inhibits its enzymatic activity (Vadas et al., 2011).
Upon growth factor stimulation, the SH2 domains of p85 bind
to the phospho-tyrosine residues on the receptor protein kinases
or adaptor proteins such as insulin receptor substrate 1 (IRS1),
thereby activating the lipid kinase activity of PI3Ka (Cantley,
2002). Activated PI3Ka converts phosphatidylinositol-4,5-bi-
sphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate
(PIP3). The second messenger PIP3 then activates downstream
AKT signaling (Cantley, 2002).of human cancers, which opens the door for targeting the
nge to develop p110a isoform-specific inhibitors. Our results
p110amutants and IRS1may be exploited as amore acces-
nciple for treatment of patients with cancer harboring such
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Figure 1. The p110a E545K Mutant Proteins
Associate with IRS1
(A) Schematics of DLD1 genetically engineered cell
lines. ABD, adaptor-binding domain; RBD, Ras-
binding domain; C2, C2 domain; helical, helical
domain; kinase, kinase domain. WT-FLAG: DLD1
cells with the endogenous wild-type p110a tagged
with 3xFLAG.Mutant FLAG: the endogenous p110a
E545K tagged with 3xFLAG. WT only: DLD1 cells
with the mutant allele of PIK3CA deleted by
homologous recombination. Mutant only: DLD1
cells with the WT allele of PIK3CA deleted as
described in Samuels et al., 2005.
(B) The p110a WT or mutant FLAG tagged cells
were grown to full confluence and serum-starved
for 24 hr before harvest. Cell lysate from the two
cell lines were immunoprecipitated with antibody-
conjugated beads against FLAG, resolved on a
4%–20% gradient SDS-PAGE gel, and stained with
Gelcode Blue Reagent.
(C and D) Lysates from cells of the indicated ge-
notype were immunoprecipitated with antibodies
against either FLAG (C) or IRS1 (D). The im-
munocomplexes were blotted with the indicated
antibodies. Arrowheads indicate the p110a E545K
and asterisks indicate the WT p110a.
(E) HEK293 cells were transfected with a con-
struction expressing FLAG-taggedWT p110a or the
indicated tumor-derived p110a mutant together
with one expressing MYC-tagged IRS1, cells were
grown 2 days post-transfection and then serum-
starved for 24 hr. Cell lysates were immunoprecip-
itated with anti-MYC antibodies and blotted with
the indicated antibodies.
See also Figure S1.
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p110a Mutant Proteins Rewire Oncogenic SignalingMost p110a mutations occur at two hot-spot regions: an
acidic cluster (E542, E545, and Q546) in the helical domain and
a histidine residue (H1047) in the kinase domain. E545K and
H1047R are the two most frequently observed p110a somatic
mutations in human cancers. Interestingly, several recent
studies indicate that E545K and H1047R mutations exert their
oncogenic functions through distinct mechanisms. Zhao and
Vogt have shown that the helical domain and the kinase domain
mutant proteins could synergistically transform chicken embry-
onic fibroblasts (Zhao and Vogt, 2008b), suggesting that the
two mutations may induce oncogenic transformation through
different pathways. Consistently, they further demonstrated
that the p110a-helical domain mutants require the Ras-binding
domain for their transformation activities whereas the oncogenic
activity of the H1047R mutant depends on the p85-binding
domain. Pang and colleagues showed that expression of
p110a E545K produced a more severe metastatic phenotype
than that induced by expressing p110a H1047R in a breast
cancer cell line (Pang et al., 2009). The p110a H1047R, but
not p110a E545K, is found to enhance HER2-mediated transfor-
mation of immortalized mammary epithelial cells (Chakrabarty
et al., 2010). Structural analysis indicates that the p110a
H1047R mutation alters the interaction between PI3Ka and
the cell membrane, thereby activating its kinase activity (Man-584 Cancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc.delker et al., 2009). It has been suggested that the helical domain
mutations activate their enzymatic activities by disrupting the
inhibitory effect of the p85 subunits (Huang et al., 2007; Miled
et al., 2007). Here, we set out to determine how p110a E545K
and p110a H1047R differentially activate oncogenic signaling
pathways.
RESULTS
The p110a E545K Mutant, but Not the Wild-Type p110a,
Associates with IRS1
DLD1 is a CRC cell line that carries a wild-type (WT) PIK3CA
allele and a PIK3CA E545K allele. DLD1 derivatives carry only
the endogenous WT or the mutant PIK3CA allele that had been
generated previously (Figure 1A) (Samuels et al., 2005). To iden-
tify proteins that may differentially bind to WT and E545Kmutant
p110a, we used recombinant adeno-associated virus (rAAV)-
mediated homologous recombination to tag the endogenous
WT or mutant p110a with 3xFLAG at their C termini in DLD1
cells (Figure 1A; Figures S1A and S1B available online) (Zhang
et al., 2008). Under serum-starvation conditions, antibodies
against FLAG immunoprecipitated a protein of 170 kDa from
3xFLAG-tagged p110a E545K knock-in (KI) cells, but not from
the 3xFLAG-WT p110a KI cells (Figure 1B). Analysis by mass
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p110a Mutant Proteins Rewire Oncogenic Signalingspectrometry identified this protein as IRS1. This IRS1-p110a
E545K interaction was validated by immunoprecipitation under
serum-starvation conditions in three different settings. In KI
DLD1 cells, IRS1 was co-immunoprecipitated with p110a
E545K but not the WT p110a (Figure 1C; Figure S1C). Moreover,
when IRS1 was immunoprecipitated from various DLD1 deriva-
tives, p110a E545K predominantly associated with IRS1 (Fig-
ure 1D; Figure S1D). Furthermore, IRS1 is strongly associated
with mutant p110a in the mutant only DLD1 cells but its interac-
tion with the WT p110a was barely detectable in the WT-only
cells (Figure 1D; Figure S1D).
p110a-Helical Domain Mutants, but Not the Kinase
Domain Mutants, Interact with IRS1
In addition to the hot-spot mutations in the helical and kinase
domains, cancer-derived mutations also occur in the ABD
and C2 domains. We thus proceeded to test whether gain
of interaction with IRS1 occurs with other p110a mutations.
We constructed a FLAG-tagged p110a expression plasmid
and generated frequently observed tumor-derived p110a
mutations by site-directed mutagenesis. The p110a WT or
mutant plasmids were coexpressed with a MYC-tagged IRS1
construct in HEK293 cells for immunoprecipitations. As shown
in Figure 1E and Figure S1E, in addition to the E545K muta-
tion, other hot-spot p110a mutations in the helical domain,
including the E542K, E545A, E545G, and Q546K, gain interac-
tion with IRS1 under serum-starvation conditions. In contrast,
however, hot-spot mutations in the kinase domain, H1047R,
H1047L, and G1049R, failed to interact with IRS1. Interestingly,
relatively rare mutations including K111N in the ABD domain,
N345K in the C2 domain, and M1043L in the kinase domain
also interact with IRS1, whereas other rare mutations including
R88Q in the ABD domain, C420R mutations in the C2 domain
and P539R in the helical domain, failed to interact with IRS1
(Figure 1E).
Interaction between the Helical Domain Mutant p110a
and IRS1 Does Not Require p85 or IRS1 Phosphorylation
Given that p110a is normally brought to the IRS1 complex
through the interaction between the SH2 domain of p85 and
phosphorylated tyrosine (pY) residues of IRS1, it was important
to determine whether the p110a E545K-IRS1 interaction
required p85 and tyrosine phosphorylation of IRS1. As shown
in Figure 2A and Figure S2A, p110a E545K, but not the WT
p110a, robustly associated with IRS1 under serum-starvation
conditions in which tyrosine phosphorylation of IRS1 was unde-
tectable, suggesting that the p110a E545K-IRS1 interaction is
independent of IRS1 tyrosine phosphorylation. It appeared that
the p110a E545K-IRS1 interaction also did not require p85
because a truncated p110a E545K lacking the ABD domain
required for p85 binding (Zhao and Vogt, 2008b) still associated
with IRS1 (Figure 2B; Figure S2B). We then proceeded to deter-
mine whether p85 proteins were required for the interaction
between p110a E545K and IRS1 under physiologic conditions.
This was accomplished by knocking out PIK3R2 (encodes
p85b) in the p110amutant only DLD1 cells using rAAV-mediated
homologous recombination (Figures 2C and 2D; Figure S2C) and
knocking down p85a with a siRNA in the p85b knockout (KO)
cells (Figure 2E). As shown in Figure 2E and Figure S2D, ablationof p85a and p85b enhanced rather than inhibited the interaction
between p110a E545K and IRS1, suggesting that not only p85
proteins were not required, but also may compete with IRS1
for binding to p110a E545K. However, ablation of both p85
proteins led to destabilization of p110a protein (Figure 2E).
Together, our data suggest that p85 proteins are not required
for the interaction between p110a E545K and IRS1 but still
play a role in the protein complex through stabilization of the
mutant p110a. Consistently, p85 proteins were coimmunopreci-
pitated with p110a E545K (Figures 1C and 2A). Furthermore, gel
filtration analysis showed that p85 and p110a E545K formed a
protein complex that was larger than that formed by p85 and
the WT p110a (Figure S2E). Interestingly, p110a E545K
completely cofractionated with IRS1, while only a portion of
p85 proteins cofractionated with p110a E545K and IRS1 (Fig-
ure S2E). This result shows that the p110a E545K mutation
changes protein complex formation.
To test if IRS1 directly binds to p110a E545K, we expressed
recombinant IRS1, WT p110a, and p110a E545K in Sf9 cells
and purified these proteins to homogeneity (Figure 2F). As shown
in Figure 2G and Figure S2F, recombinant IRS1 bound directly
in vitro with p110a E545K but not WT p110a, providing further
evidence that the IRS1-p110a E545K interaction is not mediated
by p85 proteins.
Specific Regions of IRS1 Are Required for Its Interaction
with p110a E545K
The altered interaction properties of the mutant forms of p110a
prompted us to map the minimal essential regions of IRS1
required for its interaction with p110a E545K mutant protein.
For this study, we made a series of 6xHis-tagged IRS1 trunca-
tion constructs (Figures 3A and 3C). The His-tagged IRS1 pro-
teins were first expressed in Eschericia coli and purified with
Ni-NTA beads. Then the purified proteins were used to pull
down p110a from DLD1 cells expressing either the WT p110a
only or the p110a E545K mutant only. With these proteins, we
first mapped the mutant p110a interaction domain to the middle
part of IRS1 (amino acid [AA] 585–962) (Figure 3B; Figure S3A).
This fragment contains three YxxM motifs that mediate the pY-
dependent IRS1-p85 protein interaction. We thus constructed
an unphosphorylatable IRS1Y3F mutant fragment (Figure 3A).
As shown in Figure 3B and Figure S3A, this mutant fragment still
bound to p110a E545K, providing further evidence that the pro-
tein interaction between IRS1 and p110a E545K mutant is inde-
pendent of IRS1 phosphorylation. Moreover, we showed that
the middle fragment of IRS1 pulled down the p110a E545K,
but not the WT counterparts (Figure 3B). Then, we further map-
ped the interaction domains to two small regions (AA 607–623
and AA 936–962) in the middle part of IRS1 using a combination
of 6xHis-tag and GST-fusion constructs (Figures 3C–3F; Figures
S3B and S3C). When expressed in HEK293 cells, a deletion
construct of IRS1 (IRS1D) devoid of both AA 607–623 and AA
936–962 regions greatly reduced its interaction with p110a
E545K under both normal tissue culture and serum-starvation
conditions (Figures 3G and 3H; Figures S3D–S3G). In contrast,
neither of the single region deletions could interrupt the
IRS1 mutant p110a interaction (Figures S3E and S3F). Impor-
tantly, however, IRS1D did not affect the IRS1-p85 interac-
tion (Figure 3H; Figure S3D), providing further supportingCancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc. 585
Figure 2. The p110a E545K Mutant-IRS1
Interaction Does Not Require p85 Proteins
(A) DLD1 cells expressing either the wild-type allele
(WT only) or the E545K mutant allele (Mutant only)
were serum-starved for 16 hr and then treated with
either 1 mg/ml of insulin (I) or pervanadate (V) for
15 min, or left without treatment (). Cell lysates
were immunoprecipitated with anti-IRS1 antibodies
and blotted with the indicated antibodies.
(B) Myc-tagged IRS1 plasmid was cotransfected
with a FLAG-tagged full-length p110a E545K
mutant plasmid (FL), an ABD domain deletion
construct of the FLAG-tagged p110a E545Kmutant
(DABD), a FLAG-tagged full-length WT p110a or an
ABD domain deletion construct of the FLAG-tagged
WT p110a. Cells were grown for 2 days post-
transfection and then serum-starved for 24 hr.
Cell lysates were immunoprecipitated with anti-
FLAG antibodies and blotted with the indicated
antibodies.
(C) Schematic of the PIK3R2 knockout strategy is
shown.
(D) Cell lysates of the parental p110a E545K mutant
only cells and two independently-derived PIK3R2
KO clones were blotted with the indicated anti-
bodies.
(E) p110a E545K mutant only cells of the indicated
genotypes were transfected with ether a control
siRNA or a siRNA against p85a. Cell lysates were
immunoprecipitated with anti-p110a antibodies
and blotted with the indicated antibodies.
(F) Purified recombinant His-tagged Myc-IRS1, WT
p110a, and p110a E545K mutant proteins ex-
pressed in Sf9 cells were resolved on SDS-PAGE
gels. Asterisk indicates IRS1 proteins and arrow
indicates WT and mutant p110a proteins.
(G) The indicated proteins were mixed in vitro and
the mixtures were immunoprecipitated with an
anti-Myc antibody and blotted with the indicated
antibodies. Short, short exposure; Long, long
exposure.
See also Figure S2.
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require p85. Finally, similar results were also observed when
the IRS1D was expressed in p110a E545K 3xFLAG KI DLD1
cells (Figure S3H).
IRS1 Stabilizes p110a
Next, we set out to develop a system to test whether disruption
of the IRS1 mutant p110a interaction affects tumorigenicity. To
this end, we first knocked out IRS1, a single exon gene, from
DLD1 cells (IRS1 KO) using rAAV-mediated homologous recom-
bination (Figures 4A and 4B). Two independently-derived IRS1
KO clones were then chosen for further analyses. Interestingly,
p110a, but not p85, protein levels were reduced in the IRS1
KO cells in comparison to the parental cells (Figures 4B and
4C; Figure S4A), suggesting that IRS1 stabilizes p110a. It
appears that the interaction between IRS1 and p110a E545K is
required to stabilize p110a E545K, and coexpression of IRS1
with p110a in Sf9 insect cells stabilizes p110a E545K but not
the WT p110a (Figure 4D; Figure S4B).586 Cancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc.IRS1-p110a E545K Interaction Brings the Mutant p110a
to the Cytoplasmic Membrane
Given that membrane association of p110a is important for its
activation, we then determined how IRS1 affected association
of the mutant p110a protein with the membrane. Indeed, more
p110a E545K bound to cytoplasmic membrane than the WT
proteins (Figure S4C). Importantly, knockout of IRS1 in the
p110a E545K mutant only DLD1 cells reduced the amount of
membrane-bound p110a mutant proteins (Figures 4E and 4F),
supporting the conclusion that interaction between IRS1 and
p110a E545K enhances the association of p110a E545K with
the cytoplasmic membrane.
The p110a E545K-IRS1 Interaction Is Required for
In Vivo Tumor Growth
The IRS1 KO cells formed much smaller xenograft tumors
in athymic mice (Figure 5A), although IRS1 KO did not affect
clonogenicity and anchorage-independent growth of DLD1 cells
under normal tissue culture conditions (data not shown). We
Figure 3. Mapping Regions in IRS1 Required
for Its Interaction with p110aMutant Protein
(A, C, E, and G) Schematic diagrams of IRS1
deletion proteins.
(B) His-tagged IRS1 constructs as shown in (A)
were expressed in E. coli and purified using Ni-NTA
beads. The bead-bound purified recombinant
proteins were incubated with lysates made from
either the p110a mutant-only or WT-only DLD1
cells. The pull-down mixtures were blotted with an
anti-p110a antibody.
(D) Recombinant 6xHis tagged IRS1 proteins
shown in (C) were incubated with cell lysates made
from the p110a mutant-only DLD1 cells. The pull-
down mixtures were blotted with an anti-p110a
antibody.
(F) GST-fusion proteins shown in (E) were
expressed in E. coli and purified with glutathione
sepharose beads. The bead-bound proteins were
incubated with lysates made from the p110a
mutant-only DLD1 cells. The pull-down mixtures
were blotted with an anti-p110a antibody.
(H) MYC-tagged full-length IRS1 or the IRS1D
construct was cotransfected with either a WT
p110a plasmid or a p110a E545K mutant plasmid
and a HA-tagged p85 plasmid into HEK293 cells.
Cells were grown under normal culture conditions
for 48 hr and harvested for immunoprecipitation
with anti-MYC antibody. Immunocomplexes were
blotted with the indicated antibodies.
See also Figure S3.
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p110a Mutant Proteins Rewire Oncogenic Signalingreconstituted one of the two IRS1 KO clones with either full-
length Myc-IRS1 or Myc-IRS1D expression plasmid. Two stable
clones expressing each construct were chosen for in-depth
analyses. Expression levels of IRS1 in the IRS1D reconstituted
clones were similar to those of IRS1 reconstituted clones (Fig-
ure 5B). Consistent with the hypothesis that IRS1 stabilizes
p110a, IRS1, but not IRS1D, restored the p110a level to one
that was comparable to that observed in parental cells (Fig-
ure 5B; Figure S5A). Moreover, AKT phosphorylation levels
were also increased in IRS1 reconstituted cells in comparison
to those of IRS1 KO and IRS1D reconstituted clones under
serum starvation (Figure 5B; Figure S5B), suggesting that stabi-
lization of p110a by IRS1 activates downstream signaling.
Importantly, both IRS1 reconstituted clones and IRS1D reconsti-
tuted clones responded to insulin stimulation (Figure S5C),
suggesting that IRS1D does not impair cell signaling pathways
activated by growth factors. Notably, Figure 5C shows that
IRS1 reconstituted clones formed significantly bigger xenograft
tumors than IRS1D reconstituted clones. Consistently, the
IRS1-p110a interaction was also impaired in the xenograftCancer Cell 23, 583–tumors formed by the IRS1D reconstituted
cells (Figure S5D), which led to reduced
phosphorylation of AKT and Foxo1 pro-
teins (Figure S5E). These results suggest
that IRS1-p110a E545K interaction is
crucial for the mutant p110a to exert its
oncogenic functions. Unexpectedly, the
full-length IRS1 reconstituted cells formed
smaller tumors than the parental cells. Wepostulate that this difference could be caused by differences in
regulating IRS1 between the parental cells and the IRS1 recon-
stituted cells. The ectopically expressed IRS1 in the IRS1 recon-
stituted cells may not recapitulate the complex regulation of the
endogenous IRS1. In addition, the ectopically expressed IRS1
protein has a 3xMyc tag at the N terminus of the protein, which
may not provide full-function equivalency to the endogenous
IRS1 proteins.
A Peptide Derived from p110a E545K Disrupts the
p110a-Helical Domain Mutant-IRS1 Interaction
Because our results indicated that the p110a E545K-IRS1 inter-
action is required for in vivo tumor growth of the mutant CRC
cells, we set out to test whether p110a-derived peptides encom-
passing the mutation site could be constructed to disrupt this
interaction. Based on the crystal structure of p110a (Huang
et al., 2007), we first synthesized a 30-AA E545K mutant peptide
and itsWT counterpart (Figure S6A). These amino acids form two
a-helix domains flanking the mutation site. As shown in Fig-
ure S6A, the 30-AA mutant peptide inhibited the interaction593, May 13, 2013 ª2013 Elsevier Inc. 587
Figure 4. IRS1 Stabilizes p110a E545K
Mutant Protein and Brings It to Cell
Membrane
(A) Schematic of IRS1 KO targeting strategy.
(B) Cell lysates from parental and IRS1 KO cells
were blotted with antibodies against IRS1, p110a,
pan p85, and actin. KO-1 and KO-2 are two inde-
pendently-derived IRS1 KO clones.
(C) RT-PCR analysis of PIK3CA expression in
parental and IRS1 KO cells.
(D) Sf9 insect cells were infected or co-infected
with viruses expressing indicated proteins. Cell
lysates were blotted with the indicated antibodies.
(E and F) Cell lysates from p110a E545K mutant-
only cells with IRS1 WT or IRS1 KO were frac-
tionated into cytosolic (Cyto) and cytoplasmic
membrane (Mem) fractions then blotted with the
indicated antibodies (E). Percentages of mem-
brane-bound p110a are shown in (F). Quantitative
measurements are plotted as mean ± SEM. **p =
0.0006; Student’s t test.
See also Figure S4.
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p110a Mutant Proteins Rewire Oncogenic Signalingbetween p110a E545K and IRS1 when added into cell lysates,
whereas the WT peptide failed to cause any inhibition. We then
tested if peptides corresponding to only one of the two a-helical
motifs could inhibit interactions between the mutant p110a and
IRS1. These experiments demonstrated that an 18-AA mutant
peptide corresponding to the C-terminal a-helical motif dis-
played moderate inhibition in cell lysates (Figure S6B), while
the N-terminal 21-AA mutant peptide had no effect (Figure S6B).
To improve the potency of the peptide, we converted the
aforementioned 18-AA mutant peptide to a stapled macrocyclic
derivative as shown in Figure 6A. This approach exploited the
well-documented concept that peptide stapling can stabilize
the a-helical conformation of a linear peptide and potentially
enhance binding affinity toward specific targets (Walensky
et al., 2004). Moreover, this approach was taken because sta-
pled peptides are often cell-permeable (Walensky et al., 2004).
Strikingly, our stapled mutant peptide almost completely disrup-
ted the IRS1-p110a E545K interaction in cell lysates, but had no
effects on p110a-p85 interaction (Figure S6C). In contrast, the
corresponding stapled WT p110a peptide did not inhibit IRS1-
p110a E545K interactions (Figure S6C). Interestingly, as shown
in Figure S6D, the stapledmutant peptide also inhibited the inter-
action between IRS1 and DABD p110a E545K. Thus this result
provided further evidence that the protein interaction between
IRS1 and p110a E545K mutant is not mediated by p85.
Importantly, when added to cell culture medium, the stapled
mutant peptide effectively disrupted IRS1-p110a E545K interac-
tion in DLD1 cells at 50 mMconcentration (Figure 6B; Figure S6E),
demonstrating both targeting activity and cell permeability of this
stapled peptide. Furthermore, neither the linear mutant peptide588 Cancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc.nor the stapled WT peptide affected
the interaction between p110a E545K
and IRS1 when added to cultured DLD1
cells (Figure 6B), providing strong support
of the specificity and efficacy of the
stapled mutant peptide. Moreover, the
p110a E545K stapled peptide also dis-rupted protein interaction between p110a Q546P and IRS1 in
Vaco481 CRC cells (Figure 6C; Figure S6F), suggesting that
these helical domain mutant proteins share a common critical
protein interaction interface with IRS1. In support of earlier
results, it was also notable that the stapled mutant peptide
did slightly reduce the protein levels of p110a, but did not
affect levels of p85 and IRS1 (Figure 6D; Figure S6G), providing
further evidence that the protein interaction between mutant
p110a and IRS1 stabilizes p110a. Finally, consistent with the
in vitro results, the stapled mutant peptide did not interfere
with cellular p110a-p85 interaction or IRS1 phosphorylation (Fig-
ures 6B and 6D).
The p110a E545K Mutant Peptide Reduces AKT
Phosphorylation inCancer Cell Lineswith p110a-Helical
Domain Mutations
We next determined the effect of the stapled peptides on the
downstream signaling of PI3K. As shown in Figure 6E and
Figure S6H, the stapled mutant peptide, but not the WT counter-
part, reduced AKT phosphorylation in mutant-only DLD1 cells,
whereas the mutant peptide did not affect AKT phosphorylation
in WT-only DLD1 cells. Moreover, treatment of cancer cell lines
(DLD1, H460, and MDA-MB361) harboring p110a E545K (Vasu-
devan et al., 2009) and the Vaco481 cell line harboring p110a
Q546P with the stapled mutant peptide resulted in reduced
AKT phosphorylation at both T308 and S473 residues (Figure 6F;
Figure S6I). Again, in contrast, the stapledmutant peptide had no
effect on AKT phosphorylation in cancer cell lines (HCT116,
RKO, and T47D) harboring p110a H1047R (Figure 6F). Impor-
tantly, the stapled mutant peptide has no effect on the kinase
Figure 5. Disruption of p110a E545K Inter-
action with IRS1 Impairs Tumorigenicity
(A) Three million cells of the indicated genotypes
were injected subcutaneously into athymic nude
mice. Tumor sizes were measured weekly for
5 weeks starting 2 weeks after injection.
(B) IRS1 KO DLD1 cells were reconstituted with
either full-length IRS1 or IRS1D. Cell lysates of two
stable clones from each reconstitution were
blotted with the indicated antibodies.
(C) Xenograft of the indicated cell lines were es-
tablished as described in (A). Tumor sizes were
measured weekly for 5 weeks. Mice were then
sacrificed and tumors were harvested and photo-
graphed. The p value was calculated using ANOVA
analysis.
All quantitative measurements are plotted as
mean ± SEM. See also Figure S5.
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IRS1, in vitro (Figures S6J and S6K). Consistent with previous
reports that phospho-IRS1 peptide does not enhance the lipid
kinase activity of p110a E545K (Miled et al., 2007), full-length
IRS1 proteins also had no effect on the lipid kinase activity of
p110a E545K in vitro (Figures S6J and S6K). Thus, the ability
of stapledmutant peptide to reduce AKT phosphorylation in can-
cer cells harboring p110a E545K is not due to direct inhibition of
the lipid kinase activity of p110a but by disrupting the interaction
between the p110a mutant and IRS1. Consistent with the
notions that disruption of IRS1-p110a-helical domain mutant
protein interaction does not perturb AKT activation induced by
growth factors, the mutant stapled peptide had no effect on
AKT phosphorylation when these cell lines were stimulated by
insulin (Figures S6L and S6M).
The Stapled p110a E545K Mutant Peptide Specifically
Inhibits In Vivo Tumor Growth of Cancer Cells with the
Mutation
Finally, we tested whether the stapled mutant peptide can inhibit
xenograft tumor growth of DLD1 cells. Peptides were directly
injected into xenograft tumors when the tumors reached
100–150 mm3. To better control the experiment, we injected
the stapled WT peptide into tumors on the left flanks and the
stapled mutant peptide into tumors on the right flanks of the
same nude mice (Figure 7A). Tumors of similar size were alsoCancer Cell 23, 583–injected with an equal volume of water
as controls. As shown in Figure 7B, the
stapled mutant peptide treatment signifi-
cantly slowed DLD1 xenograft tumor
growth in comparison with the control
group. In contrast, the stapled WT pep-
tide did not inhibit xenograft tumor growth
of DLD1 cells. Moreover, neither the
stapled WT nor the stapled mutant pep-
tide inhibited xenograft tumor growth of
HCT116 CRC cells that harbor p110a
H1047R (Figures 7C and 7D). In the xeno-
graft tumors, the stapled mutant peptide
treatment led to reduced AKT andFoxo1 phosphorylation (Figure S7). Unlike in culture cells where
treatment of the stapledmutant peptide reduced AKT phosphor-
ylation at both T308 and S473 residues (Figures 6E and 6F), pep-
tide treatment in xenograft tumors only decreased AKT phos-
phorylation at the S473 residue (Figure S7), suggesting that the
microenvironment in xenograft tumors is more complex than
that in in vitro culture conditions. Consistent with our observa-
tion, several studies have indicated that phosphorylation of
AKT T308 and S473 are regulated differentially (Hemmings and
Restuccia, 2012).
DISCUSSION
Our data demonstrate that the p110a-helical domain mutant
proteins gain interaction with IRS1 in the absence of growth fac-
tor stimulation and that this mutant-specific protein interaction is
independent of binding of p85 to phospho-IRS1 (see Figure 8 for
our proposed model). Therefore, our study establishes a para-
digm in which a tumor-derived mutant protein exerts its onco-
genic functions by rewiring an oncogenic signaling pathway.
Our observations also have important therapeutic implications.
The discovery of frequent mutations of PIK3CA in human cancer
provides a strong rationale for inhibition of mutated p110a
activities for targeted cancer therapy (Samuels et al., 2005).
However, it has remained a challenge to develop p110a iso-
form-specific inhibitors (Liu et al., 2009). Our data suggest that593, May 13, 2013 ª2013 Elsevier Inc. 589
Figure 6. A Stapled p110a E545K Mutant
Peptide Disrupts the Interaction between
the Mutant p110a and IRS1
(A) Schematic diagram of linear and stapled WT
and mutant peptides derived from p110a.
(B) Linear or stapled WT and mutant peptide were
added into culture medium of the p110a E545K
3xFLAG KI cells for 16 hr. Cell lysates were
immunoprecipitated with beads conjugated with
anti-FLAG antibodies and then blotted with the
indicated antibodies.
(C) Vaco481 CRC cells were treated with the
stapled mutant peptides at the indicated concen-
tration. Cell lysates were immunoprecipitated with
anti-p110a antibodies and then blotted with the
indicated antibodies.
(D) The indicated cell lines were treated with the
stapled mutant peptide. Cell lysates were blotted
with the indicated antibodies.
(E) The indicated cancer cell lines were treated or
untreated with stapled WT or mutant peptide at
50 mM for 2 hr. Cell lysates were blotted with the
indicated antibodies.
(F) The indicated cancer cell lines were treated
with or without 50 mMof stapled mutant peptide for
2 hr. Cell lysates were blotted with the indicated
antibodies.
See also Figure S6.
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p110a Mutant Proteins Rewire Oncogenic Signalingdisruption of the interactions between helical domain p110a
mutants and IRS1 may be exploited as a more accessible tar-
geted therapy approach for patients having cancers harboring
such mutations. Increasing evidence suggests that protein-
protein interactions are druggable targets (White et al., 2008).
In fact, small molecules that inhibit MDM2-p53 interaction are
being tested in clinical trials to treat patients with cancer (Ess-
mann and Schulze-Osthoff, 2012). Further, given that the mutant
p110a-IRS1 interaction only exists in tumors harboring these
mutations, it is likely that drugs targeting this interaction should
have no or minimal toxicity. In this regard, an important future
direction is to delineate the protein interaction interface between
helical domain p110amutants and IRS1 by structure analyses to
provide insights to design chemical compounds that disrupt this
mutant-specific protein-protein interaction.
The current paradigm is that the helical domain mutations
weaken p110a’s interactions with the p85 regulatory subunits,
alleviate the inhibitory effect of p85, and thus increase the enzy-
matic activity of p110a (Huang et al., 2007; Miled et al., 2007). In
contrast, our results suggest that the weakened p110a-p85
interaction caused by the mutations is not sufficient for the
p110a-helical domain mutant proteins to exert their oncogenic
functions. We provide several pieces of evidence that the
p110a E545K-IRS1 interaction plays a critical role in tumorigen-
esis. Mechanistically, our data suggest that p110a E545K
mutant-IRS1 interaction activates the mutant p110a lipid kinase590 Cancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc.by facilitating the localization of the
mutant enzyme complexes from cytosol
to plasma membrane and by stabilizing
the mutant p110a proteins. We propose
that the helical domain mutations of
p110a, as well as some of the mutationsin the ABD and C2 domains, induce conformational changes
that cause p110a to acquire a direct protein interaction with
IRS1, which does not require IRS1 tyrosine phosphorylation
and p85 proteins. Indeed, a recent study shows that oncogenic
mutations of p110a in various domains induce conformation
changes of the protein that may affect its structural interactions
(Burke et al., 2012).
Lastly, our studymay also provide an explanation for observed
different phenotypes produced by the helical and kinase domain
mutations. Using isogenic breast cancer cell lines, Becker and
colleagues demonstrated that expression of p110a-helical
domain mutants increase sensitivity of cancer cells to chemo-at-
tractants and induce much stronger metastatic phenotypes than
the H1047R kinase domain mutant (Pang et al., 2009). These
phenotypic differences cannot be simply explained by the
increased enzymatic activities of the helical and kinase domain
mutations. In fact, Vasudevan and colleagues observed that
the basal levels of phospho-AKT are lower in cancer cell lines ex-
pressing p110a-helical domain mutants compared to cell lines
expressing the H1047R kinase domain mutant (Vasudevan
et al., 2009). Consistently, when complexed with p85 regulatory
subunit, p110a H1047R displays higher lipid kinase activity
in vitro than p110a E545K (Samuels et al., 2005). We show
here that the p110a-helical domain mutants, but not the kinase
domain mutant, directly associate with IRS1 without growth fac-
tor stimulation. In this regard, we suggest that the p110a-helical
Figure 7. Stapled p110a E545K Mutant Pep-
tide Inhibits Xenograft Tumor Growth of
Cancer Cells Harboring the p110a E545K
Mutation
(A and B) Five million DLD1 cells were injected
subcutaneously and bilaterally into athymic nude
mice. Once the xenograft tumors reach 100–
150mm3, the left side tumorswere injectedwith the
stapled WT peptide and the right side tumors were
injected with the stapled mutant peptide daily for
14 days. Ten tumors of similar size in five other
athymic nude mice were injected with an equal
amount of water as controls. Tumor sizes were
measured every 2 days. Representative pictures of
mice injectedwith the peptides are shown in (A) and
quantitative measurements are shown in (B).Green
arrows indicate tumors treated with the stapled WT
peptide and the red arrows indicate tumors treated
with the stapled mutant peptide. The p value was
calculated using ANOVA analysis.
(C andD) Identical experiments as described above
were performed with HCT116 cells.
All quantitative measurements are plotted as
mean ± SEM.
See also Figure S7.
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p110a Mutant Proteins Rewire Oncogenic Signalingdomainmutant-IRS1 complexes may contain additional proteins
that do not exist in the p110a kinase domainmutant protein com-
plexes, thereby producing distinct phenotypes. Moreover, we
demonstrate that p110a-helical domain mutant-IRS1 protein
interaction does not require p85, which also provides an expla-
nation to the observation that the helical domain mutants of
p110a do not require the binding of p85 to transform chicken em-
bryonic fibroblasts (Zhao and Vogt, 2008b). However, Zhao and
Vogt’s study indicates that Ras-binding activity is still required
for the helical domainmutants of p110a to exert their transforma-
tion activities. It was also reported that interaction between Ras
and p110a enhances the substrate binding ability of p110a (Pa-
cold et al., 2000). We postulate that although IRS1 brings
p110a-helical domain mutant protein to cell membrane, the
mutant proteins also require RAS-binding to induce a conforma-
tional change to accommodate PIP2.
EXPERIMENTAL PROCEDURES
Tissue Culture
Colorectal cancer (CRC) cell lines DLD1, HCT116, Vaco481 and genetically en-
gineered CRC cell lines were maintained in McCoy’s 5A medium containing
10% fetal bovine serum (FBS). Lung cancer cell line H460 and breast cancer
cell line T47D were cultured in RPMI 1640 medium plus 10% of FBS. Breast
cancer cell line MDA-MB361 was maintained in Leibovitz’s L-15 medium with
20% FBS. Human embryonic kidney HEK293 cells were cultured in DMEM
mediumcontaining 10%FBS.Mammalian cellswere transfectedwith Lipofect-
amine in accordance with the manufacturer’s instructions (Invitrogen).
Somatic Gene Targeting
The targeting vectors were constructed with the USER system and targeted
cells were generated as described previously (Du et al., 2010). Briefly, vector
armswere created by PCR from normal humanDNA using HiFi Taq (Invitrogen)
and validated by sequencing prior to virus production and infection. The
parental DLD1 cells were purchased from ATCC (American Type CultureCollection) and infected with indicated rAAV viruses. Stable G418-resistant
clones were then selected for PCR screening as reported. When relevant, tar-
geted clones were genotyped by RT-PCR and sequencing when necessary.
Primers for targeting vector construction and PCR screening are listed in the
Supplemental Experimental Procedures.
Immunoprecipitation and Immunoblotting
For Co-immunoprecipitation (Co-IP), cells were harvested, washed with PBS,
and then lysed in IP buffer (50 mM Tris [pH 7.4], 150mMNaCl, 5 mM EDTA [pH
8.0], 0.5% NP40, 1 mM PMSF, complete Protease Inhibitor Cocktail tablet
[Roche]; supplemented with phosphatase inhibitors [1 mM Na3VO4, 20 mM
NaF, 0.1 mM b-glycerophosphate, 20 mM sodium pyrophosphate] when
necessary). For immunoblotting (IB) of phospho-specific proteins, unless
stated otherwise, cells were lysed in urea buffer (100 mM NaH2PO4, 10 mM
Tris-HCl, 8 M Urea, 1 mM Na3VO4, 20 mM NaF, 0.1 mM b-glycerophosphate,
20 mM sodium pyrophosphate, supplemented with complete Protease
Inhibitor Cocktail tablet [Roche], pH 8.0). Lysates were then cleared by centri-
fugation (14,000 rpm, 10 min) and protein concentration in supernatants was
determined with a BCA protein assay kit (Pierce, Rockford, IL). Equal amounts
of total protein were used for IP or IB as described (Zhang et al., 2007; Zhao
et al., 2010).
In Vitro Binding Assay
The 6xHis-MYC-IRS1 baculoviral vector was constructed using the bac-to-
bac expression system (Invitrogen). The 6 3 His-p110a WT and 6 3 His-
p110a E545K baculoviral vectors were kind gifts from Dr. Bert Vogelstein.
These recombinant proteins were expressed in Sf9 cells and purified using
Ni-NTA agarose beads as described (Yu et al., 2008). For in vitro binding,
100 ng of purified 6 3 His-MYC-IRS1 proteins were first attached to anti-
Myc antibody-bound beads and then incubated with the purified 6 3 His-
p110a WT or 6 3 His-p110a E545K proteins in 1 ml of IP buffer. The
protein-bound beads were washed three times for western blot analysis.
Pull-Down Assay
His-tagged or GST-tagged truncated IRS1 plasmids were constructed with
PCR-based subcloning using USER system. Each construct was transformed
into E. coli strain BL21. Recombinant protein expression was induced withCancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc. 591
Figure 8. A Model of Growth Factor Independent Activation of the
p110a E545K Mutant Signaling Pathway
(A) When normal cells are stimulated by growth factors, p110a is brought to
cell membrane through binding of p85 to phospho-IRS1, whereby converting
PIP2 to PIP3.
(B) In cancer cells harboring a p110a-helical domain mutation, the p110a
mutant directly binds to IRS1, thereby being recruited to the cell membrane
and converting PIP2 to PIP3.
Cancer Cell
p110a Mutant Proteins Rewire Oncogenic Signaling0.2 mM IPTG at 16C overnight. His-tagged and GST-fusion proteins were
purified using either Ni-NTA agarose beads or Glutathione Sepharose 4B
beads according to manufacturer’s instructions. The purified recombinant
proteins were incubated with cell lysates prepared as described previously.
Peptide Competition Assay
For in vitro peptide competition assay, the p110a mutant-FLAG-tagged cells
were grown to 90% confluency, serum-starved overnight, and lysed as
described previously. Peptides were then added to the cell lysates, incubated
for 30 min at 4C and followed by immunoprecipitation assay.
Xenografts
Animal experiments were approved by the Case Western Reserve University
Animal Care and Use Committee. As described in (Zhang et al., 2011), 3 million
cells were injected subcutaneously into the flanks of 4- to 6-week-old female
athymic nudemice. Tumor volume wasmeasured with electronic calipers, and
volumes were calculated as length 3 width2/2.
Peptide Treatment of Xenograft Tumor
Five-week-old male athymic nude mice were injected with 5 million cells sub-
cutaneously and bilaterally. When tumor sizes reached 100–150 mm3, 10mice
with similar sized tumors on both flanks were selected. The left flank tumors
were injected with stapled WT p110a peptide, whereas the right flank tumors
were injected with stapled p110a E545K mutant peptide. Each tumor was in-
jected with 250 mg of peptide daily for 14 days. Control xenograft tumors were592 Cancer Cell 23, 583–593, May 13, 2013 ª2013 Elsevier Inc.injected with an equal volume of water. The tumor sizes were measured every
2 days.
SUPPLEMENTAL INFORMATION
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